Pre-made Bimagrumab benchmark antibody ( Whole mAb, anti-ACVR2B therapeutic antibody, Anti-ACTRIIB/ActR-IIB/HTX4 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bimagrumab biosimilar, Whole mAb, Anti-ACVR2B Antibody: Anti-ACTRIIB/ActR-IIB/HTX4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.
| Products Name (INN Index) | Pre-Made Bimagrumab biosimilar, Whole mAb, Anti-ACVR2B Antibody: Anti-ACTRIIB/ActR-IIB/HTX4 therapeutic antibody |
|---|---|
| INN Name | Bimagrumab |
| Target | ACVR2B |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 5nhr:HL:AB |
| 99% SI Structure | 5nhw:HL/5nh3:HL:IM/5ngv:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | MorphoSys,Novartis |
| Conditions Approved | NA |
| Conditions Active | Cachexia,Muscular atrophy,Type 2 diabetes mellitus |
| Conditions Discontinued | Inclusion body myositis |
| Development Tech | MorphoSys HuCAL Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | ACVR2B |
| Package |
